Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

107,076 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Acquired MET Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non-Small Cell Lung Cancer.
Li A, Yang JJ, Zhang XC, Zhang Z, Su J, Gou LY, Bai Y, Zhou Q, Yang Z, Han-Zhang H, Zhong WZ, Chuai S, Zhang Q, Xie Z, Gao H, Chen H, Wang Z, Wang Z, Yang XN, Wang BC, Gan B, Chen ZH, Jiang BY, Wu SP, Liu SY, Xu CR, Wu YL. Li A, et al. Among authors: zhang xc, zhang q, zhang z. Clin Cancer Res. 2017 Aug 15;23(16):4929-4937. doi: 10.1158/1078-0432.CCR-16-3273. Epub 2017 Apr 10. Clin Cancer Res. 2017. PMID: 28396313
Analysis of resistance mechanisms to abivertinib, a third-generation EGFR tyrosine kinase inhibitor, in patients with EGFR T790M-positive non-small cell lung cancer from a phase I trial.
Zhang YC, Chen ZH, Zhang XC, Xu CR, Yan HH, Xie Z, Chuai SK, Ye JY, Han-Zhang H, Zhang Z, Bai XY, Su J, Gan B, Yang JJ, Li WF, Tang W, Luo FR, Xu X, Wu YL, Zhou Q. Zhang YC, et al. Among authors: zhang xc, zhang z. EBioMedicine. 2019 May;43:180-187. doi: 10.1016/j.ebiom.2019.04.030. Epub 2019 Apr 23. EBioMedicine. 2019. PMID: 31027916 Free PMC article.
High SHP2 expression determines the efficacy of PD-1/PD-L1 inhibitors in advanced KRAS mutant non-small cell lung cancer.
Feng HB, Chen Y, Xie Z, Jiang J, Zhong YM, Guo WB, Yan WQ, Lv ZY, Lu DX, Liang HL, Xu FP, Yang JJ, Yang XN, Zhou Q, Zhang DK, Zhang Z, Chuai SK, Zhang HH, Wu YL, Zhang XC. Feng HB, et al. Among authors: zhang dk, zhang xc, zhang z, zhang hh. Thorac Cancer. 2021 Oct;12(19):2564-2573. doi: 10.1111/1759-7714.14137. Epub 2021 Sep 6. Thorac Cancer. 2021. PMID: 34490728 Free PMC article.
EGFR L792H and G796R: Two Novel Mutations Mediating Resistance to the Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib.
Zhang Q, Zhang XC, Yang JJ, Yang ZF, Bai Y, Su J, Wang Z, Zhang Z, Shao Y, Zhou Q, Kang J, Ke EE, Zhang YC, Dong ZY, Chen ZH, Tu HY, Zhong WZ, Yang XN, Wu YL. Zhang Q, et al. Among authors: zhang yc, zhang xc, zhang z. J Thorac Oncol. 2018 Sep;13(9):1415-1421. doi: 10.1016/j.jtho.2018.05.024. Epub 2018 May 30. J Thorac Oncol. 2018. PMID: 29857056 Free article.
Clinical Utility of Cerebrospinal Fluid Cell-Free DNA as Liquid Biopsy for Leptomeningeal Metastases in ALK-Rearranged NSCLC.
Zheng MM, Li YS, Jiang BY, Tu HY, Tang WF, Yang JJ, Zhang XC, Ye JY, Yan HH, Su J, Zhou Q, Zhong WZ, Yang XN, Guo WB, Chuai S, Zhang Z, Chen HJ, Wang Z, Liu C, Wu YL. Zheng MM, et al. Among authors: zhang xc, zhang z. J Thorac Oncol. 2019 May;14(5):924-932. doi: 10.1016/j.jtho.2019.01.007. Epub 2019 Jan 17. J Thorac Oncol. 2019. PMID: 30659989 Free article.
First-in-Human Phase I Study of AC0010, a Mutant-Selective EGFR Inhibitor in Non-Small Cell Lung Cancer: Safety, Efficacy, and Potential Mechanism of Resistance.
Ma Y, Zheng X, Zhao H, Fang W, Zhang Y, Ge J, Wang L, Wang W, Jiang J, Chuai S, Zhang Z, Xu W, Xu X, Hu P, Zhang L. Ma Y, et al. Among authors: zhang l, zhang z, zhang y. J Thorac Oncol. 2018 Jul;13(7):968-977. doi: 10.1016/j.jtho.2018.03.025. Epub 2018 Apr 4. J Thorac Oncol. 2018. PMID: 29626621 Free article. Clinical Trial.
107,076 results
You have reached the last available page of results. Please see the User Guide for more information.